1. Home
  2. ICD-10-PCS Index
  3. New Technology
  4. Anatomical Regions
  5. Introduction
  6. XW01329
Version 2025
Billable Code

2025 ICD-10-CM Procedure Code XW01329

Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

ICD-10-PCS Code:
XW01329
ICD-10-PCS Code for:
Introduce Talquetamab in Subcu, Perc, New Tech 9
Is Billable?
Yes - Valid for Submission
Code Navigator:

XW01329 is a billable procedure code used to specify the performance of introduction of talquetamab antineoplastic into subcutaneous tissue, percutaneous approach, new technology group 9. The code is valid for the year 2025 for the submission of HIPAA-covered transactions. The procedure code involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

XW01329 PCS Table

In an PCS table each code is represented by up seven alphanumeric characters, with each character in the table respresenting different aspects of the procedure. In the table provided below, each row represents an individual character and includes information about the character's position, designation, label, and procedure notes. For this PCS table the procedure code is in the new technology section and is part of the anatomical regions body system, classified under introduction operation. The applicable bodypart for this procedure code is subcutaneous tissue.

Position Designation Character Label Procedures Notes
1 Section X New Technology
2 Body System W Anatomical Regions
3 Operation 0 Introduction

Involves:
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
4 BodyPart 1 Subcutaneous Tissue  
5 Approach 3 Percutaneous

Involves:
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
6 Device/Substance/Technology 2 Talquetamab Antineoplastic Includes:
  • TALVEY(tm)
7 Qualifier 9 New Technology Group 9

Replacement Code

XW01329 replaces the following previously assigned ICD-10-PCS code(s):

  • 3E01305 - Introduction of Oth Antineoplastic into Subcu, Perc Approach
  • 3E01305 - Introduction of Oth Antineoplastic into Subcu, Perc Approach
  • 3E01305 - Introduction of Oth Antineoplastic into Subcu, Perc Approach
  • 3E01305 - Introduction of Oth Antineoplastic into Subcu, Perc Approach
  • 3E01305 - Introduction of Oth Antineoplastic into Subcu, Perc Approach
  • 3E01305 - Introduction of Oth Antineoplastic into Subcu, Perc Approac

Other ICD-10-PCS Codes Used for Introduction Subcutaneous Tissue


  • XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
  • XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW01X27 Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

What is ICD-10-PCS?

The ICD-10 Procedure Coding System (ICD-10-PCS) is a catalog of procedural codes used by medical professionals for hospital inpatient healthcare settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates. The 2025 ICD-10-PCS codes are to be used for discharges occurring from October 1, 2024 through September 30, 2025.

Each ICD-10-PCS code has a structure of seven alphanumeric characters and contains no decimals. The first character defines the major "section". Depending on the "section" the second through seventh characters mean different things.